Title: Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
Authors: Deenik, Wendy ×
van der Holt, Bronno
Verhoef, Gregor
Smit, Willem M
Kersten, Marie J
Kluin-Nelemans, Hanneke C
Verdonck, Leo F
Ferrant, Augustin
Schattenberg, Anton V M B
Janssen, Jeroen J W M
Sonneveld, Pieter
van Marwijk Kooy, Marinus
Wittebol, Shulamit
Willemze, Roelof
Wijermans, Pierre W
Westveer, Petra H M
Beverloo, H Berna
Valk, Peter
Löwenberg, Bob
Ossenkoppele, Gert J
Cornelissen, Jan J #
Issue Date: Mar-2008
Publisher: W.B. Saunders
Series Title: Blood vol:111 issue:5 pages:2581-2588
Abstract: The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myeloid leukemia (CML). Patients received 2 cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1-7) in conjunction with imatinib (200 mg, 400 mg, 600 mg, or 800 mg), according to predefined, successive dose levels. All dose levels proved feasible. Seven dose-limiting toxicities (DLTs) were observed in 302 cycles of chemotherapy, which were caused by streptococcal bacteremia in 5 cases. Intermediate-dose cytarabine (1000 mg/m(2)) prolonged time to neutrophil recovery and platelet recovery compared with a standard dose (200 mg/m(2)). High-dose imatinib (600 mg or 800 mg) extended the time to platelet recovery compared with a standard dose (400 mg). More infectious complications common toxicity criteria (CTC) grade 3 or 4 were observed after intermediate-dose cytarabine compared with a standard-dose of cytarabine. Early response data after combination therapy included a complete cytogenetic response in 48% and a major molecular response in 30% of patients, which increased to 46% major molecular responses at 1 year, including 13% complete molecular responses. We conclude that combination therapy of escalating dosages of imatinib and cytarabine is feasible. This study was registered at as no. CKTO-2001-03.
ISSN: 0006-4971
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hematology Section (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science